Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 131,600 shares, a growth of 15.0% from the October 31st total of 114,400 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 36,100 shares, the days-to-cover ratio is currently 3.6 days.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on CYTH shares. HC Wainwright reissued a “neutral” rating and issued a $0.95 target price (down previously from $3.00) on shares of Cyclo Therapeutics in a report on Friday, August 23rd. Maxim Group reissued a “hold” rating on shares of Cyclo Therapeutics in a research note on Tuesday, August 27th. Finally, Ascendiant Capital Markets reduced their target price on shares of Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating for the company in a research note on Monday, August 26th.

Cyclo Therapeutics Price Performance

Shares of CYTH stock traded down $0.08 during trading hours on Friday, reaching $0.64. 28,681 shares of the company’s stock were exchanged, compared to its average volume of 21,719. The company’s 50 day moving average is $0.73 and its two-hundred day moving average is $0.98. The company has a market cap of $18.41 million, a P/E ratio of -0.71 and a beta of -0.38. Cyclo Therapeutics has a 1 year low of $0.59 and a 1 year high of $2.12.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.